JPRN-UMIN000028071已完成2 期
Osimertinib combined bevacizumab in untreated epidermal growth factor receptor mutaeted non-small-cell lung cancer patients with malignant pleural and/or pericardial effusion -phase II trial- - SPIRAL II Study
Clinical Research Support Center Kyushu0 个研究点目标入组 31 人开始时间: 2017年7月4日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 31
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients whose chest drainage is no problem for pleural effusion,but who have pleurodesis. 2.Patients with pulmonary disorders such as idiopathic pulmonary fibrosis,interstitial pneumonia, pneumoconiosis,active radiation pneumonitis and drug-induced pneumonia. 3.Anamnesis and complication of hemoptysisor the following bloody sputum. bloody sputum which occurs continuously bloody sputum which needs the continuous administration of oral hemostatics bloody sputum necessary for homostatic injection. 4.Patients with cavity and tumor invasion to large vessels. 5.Infectious disorder need for intravenous injection of antibacterial drug and antimycotics. 6.Patients with corneal ulcer.7.Patients with any of the following risk of QTc prolongation: Mean resting mean corrected QT interval >470msec. Any clinically important abnormalities in rhythm,conduction or morphology of resting ECG. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events. 8.Patients who are pregnant,nursing or possibly pregnant. 9.Patients with brain metastasis accompanying symptoms. 10.Active double cancer. 11.Patients with uncontrollable diabetes mellitus. 12.Patients who have complications to be clinical problem. 13.Patients judged as severe or uncontrollable systemic disease by investigators. For example,patients is judged by investigators that the participation in the study is undesirable or that the compliance of the protocol is difficult by uncontrollable hypertension and active hemorrhagic diathesis or hepatitis B,hepatitis C and active infections such as human immunodeficiency virus infection. 14.Patients with anamneses such as refractory nausea and vomiting,chronic digestive organ disease or pharmaceutical preparation aphagia,or gastroeneterectomy that may remarkably influence osimertinib absorption. 15.Patients whose wound healing cannot be confirmed. 16.Patients without intention to prevent pregnancy during a study period.
研究者
相似试验
已完成
1 期
A phase I study of osimertinib with bevacizumab and randomized phase II study of osimertinib with or without bevacizumab in EGFR mutated, T790M positive patients who had progressed EGFR-TKIs. (WJOG8715L)ung CancerJPRN-UMIN000023761West Japan Oncology Group87
招募中
2 期
Afatinib plus Bevacizumab Combination after osimertinib failure for aDvanced EGFR-mutant non-small cell lung cancer: a multicenter prospective single arm phase II study (ABCD-study)on-small cell lung cancerJPRN-UMIN000030545Hanshin Oncology Group26
进行中（未招募）
2 期
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain MetastasesMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Neoplasm in the BrainStage IV Lung Cancer AJCC v8NCT02971501National Cancer Institute (NCI)5
已完成
不适用
A Phase Ib study of osimertinib with ramucirumab in EGFR mutated lung adenocarcinoma patients. (LY3009806-IIT-01)JPRN-UMIN000030142Wakayama Medical University6
尚未招募
Unknown
COmbination of Bevacizumab and Erlotinib Therapy in EGFR overamplified metastatic colorectal cancer with resistance or intolerance to oxaliplatin and irinotecan-based chemotherapy - A single arm, phase 2, multicenter Study (COBET)NeoplasmsKCT0009473Korea University Anam Hospital39